Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study

Cardona, Ricardo; López, Esperanza; Beltrán, Javier

doi:10.1016/j.aller.2012.07.005

Cited by 26 publications

(30 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11,12 However, some research indicated that premedication or adjusted doses greatly improved the safety of RIT. 13,14 The systemic adverse reactions in both groups showed no statistically significant differences (P >0.05). In this study, adverse reactions at the build-up phase were examined and compared between RIT and conventional immunotherapy.…”

Section: Discussionmentioning

confidence: 83%

“…This conclusion is similar to that of previous studies. 13,14 In our study, VAS, weekly administration scores, and IgG4 (a marker of ASIT induced immune tolerance) levels in peripheral serum at difference time points between the two groups were compared to evaluate their efficacy. The results demonstrated that VAS in the RIT group was lower at week 2 while the IgG4 levels were higher in the early stage of treatment, and at the point after RIT dose buildup finished 1 week later, weekly medication scores were higher in the conventional immunotherapy group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of rush allergen-specific immunotherapy in Chinese allergic rhinitis patients

Qiu

et al. 2016

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

The purpose of this prospective, open-IV clinical trial was to assess the safety and efficacy differences between Rush immunotherapy (RIT) and conventional immunotherapy in Chinese allergic rhinitis (AR) patients. The trial involved 174 patients with AR. They were divided into two groups according to their preference of therapy: RIT or conventional immunotherapy. A total of 162 patients completed a 1-year treatment course. For safety and effectiveness evaluation, the local and systemic adverse reactions were recorded throughout the initial phase of both groups. Weeks 0, 2, 5, and 17 were set as observation time points for immunoglobulin G (IgG) and IgG4. Besides that, another observation time point (Week 11) was added in for a visual analog scale (VAS) and a weekly drug dosage scale. In the RIT group, systemic adverse events of AR were similar to those of the conventional therapy group. LTB4 was descended. The VAS of the RIT group did not show a downward trend clearly, instead Week 5 was higher compared with Week 0. The weekly drug dosage scale did not indicate a significant decline, but there was a clear rise in IgG4 in the RIT group. The safety and efficacy of RIT for AR is positive, but further study is needed for improvement.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of rush allergen-specific immunotherapy in Chinese allergic rhinitis patients

Qiu

et al. 2016

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…187,188 Also, studies indicate that modified allergen extracts are associated with less adverse effects. [189][190][191][192] For aluminum hydroxide containing SCIT products, granulomas have been described from a foreign body reaction mainly caused by incorrect intradermal administration as well as contact allergic reactions, new onset of protein contact dermatitis, or a vasculitis inflammatory reactions have been reported. [193][194][195] If these reactions to SCIT occur, treatment with another aluminum hydroxide-free product is preferred (Grade D).…”

Section: Scitmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

594

705

View full text Add to dashboard Cite

drawn on data from a systematic review of the literature, more recent published studies and multistakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare. AbstractAllergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach.The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass 766 | ROBERTS, PFAAR ET AL. tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. | ME TH ODOLOGYThis Guideline was produced using the Appraisal of Guidelines forResearch & Evaluation (AGREE II) approach, 17,18 a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated. | Clarifying the scope and purpose of the guidelinesThe scope of this EAACI Guideline is multifaceted...

show abstract

“…En varias publicaciones se ha reportado que algunos pacientes pueden presentar exacerbación de los síntomas cutáneos con esta terapia; no obstante, cuando la administración se hace de forma controlada, especialmente con extractos modificados, el riesgo de reacciones sistémicas se reduce considerablemente, como se observó en un estudio retrospectivo, también en Medellín, en el cual ninguno de los 114 pacientes con dermatitis, a los cuales se les aplicaron más de 1.000 inyecciones, presentó una reacción sistémica ni tuvo que abandonar la terapia debido a la exacerbación de los síntomas durante el tratamiento (63).…”

Section: Dermatitis Atópicaunclassified

“…Las reacciones sistémicas son infrecuentes (0,1 %) y hasta el momento no se han reportado muertes por esta causa en el país (63), lo cual respondería al hecho de que solo el personal experto en centros especializados se encarga de su aplicación.…”

Section: Consideraciones Particulares Sobre La Inmunoterapia En Colombiaunclassified

Inmunoterapia con alérgenos: mecanismos de acción, impacto terapéutico y socioeconómico. Consenso de la Asociación Colombiana de Alergias Asma e Inmunología

et al. 2016

View full text Add to dashboard Cite

: idea central. Todos los autores participaron por igual en la redacción del manuscrito y la aprobaron la versión final. Las alergias constituyen un conjunto de enfermedades de gran prevalencia. Cuando los procesos alérgicos no se controlan, pueden poner en peligro la salud e, incluso, la vida de los pacientes y, además, su efecto económico y social es considerable. El objetivo de esta revisión es presentar un consenso práctico de la información científica disponible sobre el empleo de la inmunoterapia en las enfermedades alérgicas con la colaboración de varios institutos y universidades de Colombia, por solicitud de la Asociación Colombiana de Alergia, Asma e Inmunología. La revisión incluyó aspectos prácticos presentados desde el punto de vista de médicos generales, alergólogos, inmunólogos, internistas y pediatras con experiencia en el campo de las alergias. Con base en la evidencia científica actual a nivel nacional e internacional, se describió de forma detallada en qué consiste la inmunoterapia, sus indicaciones, contraindicaciones y sus beneficios para la salud, así como en el ámbito socioeconómico. Se concluyó que la inmunoterapia es efectiva y segura, y que, además, puede reducir sustancialmente el costo del tratamiento global de los pacientes alérgicos. Inmunoterapia con alérgenosPalabras clave: alérgenos, consenso, asma, anafilaxia, dermatitis, conjuntivitis, himenópteros, inmunoterapia, rinitis.doi: http://dx.doi.org/10.7705/biomedica.v36i3.3183 Allergen immunotherapy: Mechanisms of action, and therapeutic and socioeconomic impact Consensus of the Asociación Colombiana de Alergia, Asma e ImunologíaAllergies comprise a set of highly prevalent diseases. When allergic processes are not controlled, they can endanger patients' health and lives, and have an important economic and social impact. The aim of this paper is to present a practical consensus of the scientific evidence on the use of immunotherapy in allergic diseases. A collaborative review made by various institutes and universities in Colombia was carried out upon request of the Asociación Colombiana de Alergia, Asma e Imunología, led by general practitioners, allergists, immunologists, internists and paediatricians with experience in the field of allergies. As a result, based on current national and international scientific evidence, we describe in detail what immunotherapy is about, its indications, contraindications and its economic and health benefits.Conclusions show immunotherapy as a clinically effective and safe treatment, which can substantially reduce the cost of the overall treatment of allergic patients.

show abstract

Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study

Cited by 26 publications

References 33 publications

Safety and efficacy of rush allergen-specific immunotherapy in Chinese allergic rhinitis patients

Safety and efficacy of rush allergen-specific immunotherapy in Chinese allergic rhinitis patients

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Inmunoterapia con alérgenos: mecanismos de acción, impacto terapéutico y socioeconómico. Consenso de la Asociación Colombiana de Alergias Asma e Inmunología

Contact Info

Product

Resources

About